Zota Health Care Ltd
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
- Market Cap ₹ 2,886 Cr.
- Current Price ₹ 981
- High / Low ₹ 1,078 / 527
- Stock P/E 335
- Book Value ₹ 111
- Dividend Yield 0.10 %
- ROCE 5.68 %
- ROE 3.93 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 49.3%
Cons
- Stock is trading at 8.93 times its book value
- Promoter holding has decreased over last quarter: -4.29%
- Company has a low return on equity of 4.32% over last 3 years.
- Earnings include an other income of Rs.4.62 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49 | 56 | 64 | 70 | 77 | 85 | 95 | 106 | 131 | 138 | 166 | 257 | |
| 43 | 47 | 55 | 60 | 66 | 77 | 90 | 105 | 116 | 130 | 160 | 246 | |
| Operating Profit | 7 | 8 | 10 | 10 | 11 | 8 | 5 | 1 | 15 | 8 | 6 | 11 |
| OPM % | 13% | 15% | 15% | 14% | 14% | 9% | 5% | 1% | 12% | 6% | 4% | 4% |
| 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 5 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 |
| Profit before tax | 5 | 6 | 8 | 8 | 11 | 8 | 4 | -0 | 14 | 9 | 5 | 12 |
| Tax % | 33% | 33% | 34% | 34% | 36% | 29% | 29% | -47% | 25% | 24% | 31% | 27% |
| 3 | 4 | 5 | 6 | 7 | 6 | 3 | -0 | 11 | 7 | 3 | 9 | |
| EPS in Rs | 1.86 | 2.12 | 2.54 | 2.76 | 2.96 | 2.26 | 1.12 | -0.07 | 4.21 | 2.62 | 1.31 | 3.01 |
| Dividend Payout % | 38% | 34% | 28% | 52% | 72% | 32% | 89% | -1,535% | 36% | 38% | 76% | 33% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 22% |
| 3 Years: | 25% |
| TTM: | 55% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | -7% |
| TTM: | 155% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 54% |
| 1 Year: | 84% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 14 | 14 | 14 | 18 | 18 | 25 | 25 | 25 | 25 | 26 | 29 |
| Reserves | 4 | 4 | 7 | 13 | 52 | 51 | 44 | 42 | 66 | 69 | 96 | 289 |
| 5 | 5 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | |
| 13 | 15 | 20 | 23 | 22 | 21 | 20 | 19 | 34 | 30 | 37 | 62 | |
| Total Liabilities | 33 | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 173 | 380 |
| 9 | 8 | 7 | 7 | 10 | 10 | 15 | 14 | 13 | 11 | 12 | 128 | |
| CWIP | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 |
| Investments | 0 | 0 | 0 | 0 | 26 | 16 | 14 | 10 | 35 | 10 | 7 | 0 |
| 24 | 30 | 36 | 45 | 56 | 63 | 59 | 62 | 78 | 101 | 150 | 246 | |
| Total Assets | 33 | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 173 | 380 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 4 | 5 | 3 | -4 | -3 | 6 | -1 | 14 | -10 | -30 | -22 | |
| -1 | -1 | -1 | -2 | -26 | 9 | -4 | 4 | -27 | 13 | -9 | -148 | |
| -2 | -4 | -3 | -2 | 33 | -6 | -3 | -2 | 14 | -4 | 38 | 171 | |
| Net Cash Flow | 0 | 0 | 1 | -1 | 2 | -1 | -1 | 1 | 1 | -1 | -1 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 79 | 77 | 90 | 88 | 109 | 95 | 112 | 99 | 107 | 115 | 162 | 146 |
| Inventory Days | 134 | 175 | 141 | 193 | 174 | 207 | 139 | 139 | 116 | 148 | 139 | 140 |
| Days Payable | 104 | 116 | 126 | 148 | 118 | 103 | 82 | 77 | 76 | 102 | 107 | 109 |
| Cash Conversion Cycle | 108 | 135 | 105 | 133 | 165 | 199 | 169 | 161 | 147 | 161 | 194 | 177 |
| Working Capital Days | 74 | 87 | 85 | 115 | 151 | 175 | 152 | 143 | 112 | 153 | 204 | 177 |
| ROCE % | 27% | 32% | 36% | 33% | 23% | 11% | 6% | -2% | 18% | 9% | 5% | 6% |
Documents
Announcements
-
Alteration Of Capital and Fund Raising-XBRL
10 June 2025 - ZOTA HEALTH CARE LIMITED has informed regarding Allotment of Securities
-
Allotment of Securities
10 June 2025 - Allotment of 3.03 lakh shares at Rs.509 each on warrant conversion, raising Rs.11.56 crore.
-
Analysts/Institutional Investor Meet/Con. Call Updates
4 June 2025 - Zota Healthcare Q4 FY25 earnings call: 62% revenue growth, 1,582 stores, aggressive expansion plans.
-
Copy of Newspaper Publication
31 May 2025 - Published newspaper ads for audited financial results Q4 and FY ended March 31, 2025.
-
Analysts/Institutional Investor Meet/Con. Call Updates
30 May 2025 - Audio recording link of Q4FY25/FY25 earnings call available on company website.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Apr 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Dec 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Business segments
Domestic sales (49% of FY21 revenue)[1] The is the oldest division and involves direct distribution of generic drugs, OTC products, and other pharmaceutical products through Company’s distribution network across India. Co. has 1050+ distributors across India and 3000+ products in its portfolio.